Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 6

Severity of COPD at initial spirometry-confirmed diagnosis: data from medical charts and administrative claims

Authors Mapel DW, Dalal A, Blanchette CM, Petersen H, Ferguson GT

Published 9 November 2011 Volume 2011:6 Pages 573—581

DOI https://doi.org/10.2147/COPD.S16975

Review by Single-blind

Peer reviewer comments 2

Douglas W Mapel1, Anand A Dalal2, Christopher M Blanchette3,4, Hans Petersen3, Gary T Ferguson5
1Lovelace Clinic Foundation, Albuquerque, NM, USA; 2US Health Outcomes, GlaxoSmithKline, Research Triangle Park, NC, USA; 3Lovelace Respiratory Research Institute, Kannapolis, NC, USA; 4University of North Carolina Eshelmen School of Pharmacy, Chapel Hill, NC, USA; 5Pulmonary Research Institute of Southeast Michigan, Livonia, MI, USA

Purpose: This study was conducted to determine COPD severity at the time of diagnosis as confirmed by spirometry in patients treated in a US managed care setting.
Patients and methods: All patients with one or more inpatient stays, one or more emergency department visits, or two or more outpatient visits with diagnosis codes for COPD during 1994–2006 were identified from the Lovelace Patient Database. From this group, a subset of continuously enrolled patients with evidence in claims of a first available pulmonary function test or pulmonary clinic visit and a confirmatory claim for a COPD diagnosis was selected. Medical chart abstraction was undertaken for this subset to gather information for diagnosis and severity staging of each patient based on the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria for COPD.
Results: Of the 12,491 patients with a primary or secondary COPD diagnosis between 1994 and 2006, there were 1520 continuously enrolled patients who comprised the study cohort. Among the 648 eligible records from patients with evidence of a pulmonary function test, 366 were identified by spirometry as having COPD of GOLD stage I or higher (average percentage of predicted forced expiratory volume in 1 second: 60%): 19% were diagnosed at the stage of mild disease (GOLD stage I); 50% at moderate disease (GOLD stage II); and 31% at severe or very severe disease (GOLD stage III or IV, respectively). The majority of patients in these groups were not receiving maintenance treatment.
Conclusion: The results demonstrate a very low incidence of early-stage diagnosis, confirmed by a pulmonary function test, of COPD in a large US sample and support calls for increased screening for COPD and treatment upon diagnosis.

Keywords: lung function, Global Initiative for Chronic Obstructive Lung Disease (GOLD), detection, early treatment

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Treatment patterns of chronic obstructive pulmonary disease in employed adults in the United States

Diette GB, Dalal AA, D’Souza AO, Lunacsek OE, Nagar SP

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:415-422

Published Date: 24 February 2015

Direct costs of chronic obstructive pulmonary disease among managed care patients

Anand A Dalal, Laura Christensen, Fang Liu, et al

International Journal of Chronic Obstructive Pulmonary Disease 2010, 5:341-349

Published Date: 30 September 2010

Readers of this article also read:

Tumor-targeted and pH-controlled delivery of doxorubicin using gold nanorods for lung cancer therapy

Amreddy N, Muralidharan R, Babu A, Mehta M, Johnson EV, Zhao YD, Munshi A, Ramesh R

International Journal of Nanomedicine 2015, 10:6773-6788

Published Date: 29 October 2015

Long-term effects of gastrectomy in patients with spirometry-defined COPD and patients at risk of COPD: a case-control study

Saito H, Nomura K, Abe S, Motegi T, Ishii T, Hattori K, Kusunoki Y, Gemma A, Kida K

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:2311-2318

Published Date: 29 October 2015

Systemic cytokine signaling via IL-17 in smokers with obstructive pulmonary disease: a link to bacterial colonization?

Andelid K, Tengvall S, Andersson A, Levänen B, Christenson K, Jirholt P, Åhrén C, Qvarfordt I, Ekberg-Jansson A, Lindén A

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:689-702

Published Date: 27 March 2015

Comorbidity and health-related quality of life in patients with severe chronic obstructive pulmonary disease attending Swedish secondary care units

Sundh J, Johansson G, Larsson K, Lindén A, Löfdahl CG, Janson C, Sandström T

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:173-183

Published Date: 22 January 2015

Lung function decline in COPD

Tantucci C, Modina D

International Journal of Chronic Obstructive Pulmonary Disease 2012, 7:95-99

Published Date: 9 February 2012

Factors associated with good self-rated health and quality of life in subjects with self-reported COPD

Arne M, Lundin F, Boman G, Janson C, Janson S, Emtner M

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:511-519

Published Date: 7 October 2011

Spirometric testing on World COPD Day

Tanja Grzetic-Romcevic, Boris Devcic, Silvana Sonc,

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:141-146

Published Date: 10 February 2011